Fig. 3: Antigen uptake and immune cell activation by mU@OMVs. | Nature Communications

Fig. 3: Antigen uptake and immune cell activation by mU@OMVs.

From: Bacterial outer membrane vesicle based versatile nanosystem boosts the efferocytosis blockade triggered tumor-specific immunity

Fig. 3

a CLMS images of BMDCs with PBS, OVA, or OVA + mU@OMVs treatment for 12 h. OVA (PE-labeled, red); BMDCs (FITC-conjugated anti-CD11c labeled, green); cell nucleus (Hoechst 33342, blue). Scale bar: 50 μm. b, c Flow cytometry and quantification of the internalization after different treatments. d Schematic illustration of the experiment of immune cell activation. TAAs were incubated with different vesicles and added into BMDCs for 24 h. Then, parts of BMDCs were collected and cultured with T cells for a further 24 h. The cells and the supernatant from different treatments were collected for flow cytometry assay or ELISA. e–h Expression levels of CD80, CD86, MHC-II, and MHC-I on BMDCs by flow cytometry. i, j Flow cytometry and quantification of expression levels of CD69 gated on CD8+ T cells. Data in c, e–h, j are presented as mean ± s.d. (n = 3 biologically independent cells). Statistically significant differences between groups were identified by unpaired two-tailed Student’s t-test. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. Source data are provided as a Source Data file.

Back to article page